blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3212210

EP3212210 - COMBINATION THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.10.2020
Database last updated on 22.08.2024
FormerThe patent has been granted
Status updated on  08.11.2019
FormerGrant of patent is intended
Status updated on  14.05.2019
FormerExamination is in progress
Status updated on  06.04.2019
FormerGrant of patent is intended
Status updated on  06.12.2018
FormerExamination is in progress
Status updated on  27.04.2018
FormerRequest for examination was made
Status updated on  04.08.2017
FormerThe international publication has been made
Status updated on  26.05.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Big DNA Ltd
22 Forth Street
Edinburgh, EH1 3LH / GB
[2019/20]
Former [2017/36]For all designated states
Big DNA Ltd
Wallace Building Roslin Biocentre
Roslin, Midlothian EH25 9PP / GB
Inventor(s)01 / MARCH, John Bernard
c/o Big DNA Ltd
22 Forth Street
Edinburgh, EH1 3LH / GB
02 / CLARK, Ewan McIntosh
c/o Big DNA Ltd
22 Forth Street
Edinburgh, EH1 3LH / GB
 [2019/50]
Former [2017/36]01 / MARCH, John Bernard
c/o Big DNA Ltd
Wallace Building
Roslin BioCentre
Roslin Midlothian EH25 9PP / GB
02 / CLARK, Ewan McIntosh
c/o Big DNA Ltd
Wallace Building
Roslin BioCentre
Roslin Midlothian EH25 9PP / GB
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2017/36]HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date15791346.827.10.2015
[2017/36]
WO2015GB53215
Priority number, dateGB2014001931130.10.2014         Original published format: GB 201419311
GB2015000068115.01.2015         Original published format: GB 201500681
GB2015000667320.04.2015         Original published format: GB 201506673
[2017/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016067010
Date:06.05.2016
Language:EN
[2016/18]
Type: A1 Application with search report 
No.:EP3212210
Date:06.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 06.05.2016 takes the place of the publication of the European patent application.
[2017/36]
Type: B1 Patent specification 
No.:EP3212210
Date:11.12.2019
Language:EN
[2019/50]
Search report(s)International search report - published on:EP06.05.2016
ClassificationIPC:A61K38/00, A61K38/05, A61K38/06, A61K38/07, A61K38/12, A61K31/4015, A61K31/407, A61K31/69, A61K45/06
[2018/49]
CPC:
A61K38/12 (EP,CN,KR,US); A61K31/69 (EP,KR,US); A61K38/06 (EP,CN,KR,US);
A61K31/4015 (EP,KR,US); A61K31/407 (EP,US); A61K38/005 (EP,US);
A61K38/05 (EP,US); A61K38/07 (EP,US); A61K45/06 (EP,KR,US);
A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP);
A61P43/00 (EP); A61K2300/00 (KR) (-)
C-Set:
A61K31/4015, A61K2300/00 (US,EP);
A61K31/69, A61K2300/00 (US,EP);
A61K38/06, A61K2300/00 (US,CN,EP);
A61K38/12, A61K2300/00 (EP,CN,US)
Former IPC [2017/36]A61K38/04, A61K38/12, A61K31/365, A61K31/69, C07D303/36, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/36]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:KOMBINATIONSTHERAPIE[2017/36]
English:COMBINATION THERAPY[2017/36]
French:POLYTHÉRAPIE[2017/36]
Entry into regional phase26.05.2017National basic fee paid 
26.05.2017Designation fee(s) paid 
26.05.2017Examination fee paid 
Examination procedure26.05.2017Examination requested  [2017/36]
26.05.2017Date on which the examining division has become responsible
10.07.2017Amendment by applicant (claims and/or description)
26.04.2018Despatch of a communication from the examining division (Time limit: M04)
17.08.2018Reply to a communication from the examining division
07.12.2018Communication of intention to grant the patent
04.04.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.05.2019Communication of intention to grant the patent
17.09.2019Fee for grant paid
17.09.2019Fee for publishing/printing paid
17.09.2019Receipt of the translation of the claim(s)
Opposition(s)14.09.2020No opposition filed within time limit [2020/47]
Fees paidRenewal fee
14.09.2017Renewal fee patent year 03
03.10.2018Renewal fee patent year 04
31.10.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.10.2015
AL11.12.2019
AT11.12.2019
CY11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
IT11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
MK11.12.2019
MT11.12.2019
NL11.12.2019
PL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
TR11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
[2022/32]
Former [2022/27]HU27.10.2015
AL11.12.2019
AT11.12.2019
CY11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
IT11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
MT11.12.2019
NL11.12.2019
PL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
TR11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2021/31]AL11.12.2019
AT11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
IT11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
NL11.12.2019
PL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2021/10]AL11.12.2019
AT11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
IT11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
PL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/51]AL11.12.2019
AT11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/47]AL11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/40]AL11.12.2019
CZ11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/37]AL11.12.2019
CZ11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
PT06.05.2020
Former [2020/36]AL11.12.2019
CZ11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
PT06.05.2020
Former [2020/35]AL11.12.2019
CZ11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/34]AL11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/32]AL11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/25]FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/23]FI11.12.2019
LT11.12.2019
LV11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/22]FI11.12.2019
LT11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
Former [2020/21]NO11.03.2020
Cited inInternational search[Y]WO2008087025  (MERCK PATENT GMBH [DE], et al) [Y] 1-21 * the whole document *;
 [XY]WO2010096627  (LISANTI MICHAEL P [US], et al) [X] 1-3,10-21 * the whole document * * claim - * [Y] 1-21;
 [Y]WO2011079015  (UNIV CALIFORNIA [US], et al) [Y] 1-21 * the whole document *;
 [Y]WO2012167870  (MERCK PATENT GMBH [DE], et al) [Y] 1-21 * the whole document * * page 5, line 21 - page 6, line 18; claim - *;
 [Y]WO2013170066  (H LEE MOFFITT CANCER CT & RES [US], et al) [Y] 1-21 * the whole document * * figure -; claim - *;
 [Y]  - ALEXEIF KISSELEV ET AL, "Proteasome Inhibitors: An Expanding Army Attacking a Unique Target", CHEMISTRY AND BIOLOGY, vol. 19, no. 1, doi:10.1016/J.CHEMBIOL.2012.01.003, ISSN 1074-5521, (20120127), pages 99 - 115, (20120112), XP028453093 [Y] 1-21 * the whole document * * figure 2 *

DOI:   http://dx.doi.org/10.1016/j.chembiol.2012.01.003
 [A]  - PRASHANT KAPOOR ET AL, "Bortezomib Combination Therapy in Multiple Myeloma", SEMINARS IN HEMATOLOGY, US, (20120701), vol. 49, no. 3, doi:10.1053/j.seminhematol.2012.04.010, ISSN 0037-1963, pages 228 - 242, XP055236438 [A] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1053/j.seminhematol.2012.04.010
 [A]  - BHANDARI M S ET AL, "Clinical trials in metastatic prostate cancer - Has there been real progress in the past decade?", EUROPEAN JOURNAL OF CANCER, PERGAMON, GB, vol. 41, no. 6, ISSN 0959-8049, (20050401), pages 941 - 953, (20050401), XP027785732 [A] 1-21 * the whole document * * paragraph [09.2] *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.